CD274 and neoplasm: However, systemic therapy with anti–PD‐1 antibody has been correlated with immune‐related side effects and may trigger an immunosuppressive response through interacting with different types of immunosuppressive cells present within the tumor microenvironment.24–26 In the study, to overcome the PD-1/PD-L1 inhibitory pathway, the autologous DC-CIK cells were in vitro directly incubated with a low-dose of pembrolizumab to generate the PD-1 blockade-activated DC-CIK cells (i.e., PD1-T cells).